Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 850 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Bipolar Disorder
Interventions: Lithium, Olanzapine, Divalproex, Risperidone, Quetiapine, Ziprasidone, Aripriprazole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 10 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Hypoxia, Apnea, Hypotension, Hypopnea
Interventions: Capnographic Monitoring; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Independence, Ohio

Conditions: Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions: Haloperidol + lorazepam, Loxapine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pain
Interventions: Thalidomide, Ibuprofen or Diazepam; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Subacute Low Back Pain
Interventions: Progressive Exercise Plan, NeuromuscularElectricalStimulation(NMES), Primary Care Management (PCM); Behavioral · Device
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 45 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fort Campbell North, Kentucky

Conditions: Psychotic Depression
Interventions: Sertraline + Olanzapine, Sertraline + Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Worcester, Massachusetts • White Plains, New York • Pittsburgh, Pennsylvania

Conditions: Opioid Overdose, Opioid Use, Opioid Use Disorder, Opioids
Interventions: EHR-Embedded Elevated-Risk Flag, EHR-Embedded Elevated-Risk Flag with Behavioral Nudges, Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Autism
Interventions: Olanzapine; Drug
Lead sponsor: Drexel University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol Withdrawal Syndrome
Interventions: Gabapentin, Benzodiazepines, Divalproex Sodium; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
Interventions: Oral Nutrition Supplement, Tube Feed, Cyproheptadine, Olanzapine, Standard of Care; Dietary Supplement · Drug · Other
Lead sponsor: Corey Hawes; Other
Eligibility: 2 Years to 19 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Complex Insomnia
Interventions: eszopiclone, Brief behavioral therapy for insomnia; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Panic Disorder, Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neonatal Abstinence Syndrome
Interventions: oral morphine, sublingual buprenorphine; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colonoscopy
Interventions: Remimazolam, Midazolam, Placebo; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Medication Abuse
Interventions: Clinical Decision Support (CDS) alerts; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 89 Years
Enrollment: 3,635 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Schizophrenia
Interventions: PF-00184562, Olanzapine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Olanzapine, Megestrol Acetate, Questionnaire Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 293
States / cities: Gilbert, Arizona • Goodyear, Arizona • Peoria, Arizona + 239 more

Conditions: Obesity
Interventions: S-309309, Midazolam, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Metastatic Breast Cancer
Interventions: LY3295668 Erbumine, Endocrine therapy, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Duarte, California • Boston, Massachusetts • San Antonio, Texas

Conditions: Healthy
Interventions: Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Normal Non-fluency
Interventions: Olanzapine; Drug
Lead sponsor: Michael Rickels; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gynecologic Cancer
Interventions: Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: JNJ-42847922, Midazolam, Warfarin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Treatment and Outcome of Early Onset Bipolar Disorder

Use of Capnography in EGD and Colonoscopy With Moderate Sedation.

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

Evaluation of a TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect

Subacute Low Back Pain in Active Duty

Sustaining Remission of Psychotic Depression

Machine-Learning Prediction and Reducing Overdoses With EHR Nudges

Long-Term Olanzapine Treatment in Children With Autism

Gabapentin for Alcohol Withdrawal Syndrome

Pediatric Oncology Nutrition Intervention Trial

Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD

Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder

Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

A Health System Wide Evaluation of Clinical Decision Support Tools to Improve PDMP Utilization and Patient Outcomes

A First In Human Study Of PF-00184562 In Healthy Volunteers

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

A Study to Assess S-309309 in Healthy and Obese Participants

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants